TScan Therapeutics, Inc.’s TCRX share price has dipped by 5.81%, which has investors questioning if this is right time to buy ...

Prime Medicine, Inc.’s PRME share price has dipped by 5.43%, which has investors questioning if this is right time to buy.

After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.

ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage ...

Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / ACCESS Newswire / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Since sharing their story online, support has poured in from across the country. Over €147,000 has been raised via GoFundMe, ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. ( Lancet Oncology) U.S.